OS Therapies to Participate in Fall 2025 Conferences and Events

• Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and human & canine patients who participated in OST-HER2 clinical trials

New York, New York--(Newsfile Corp. - October 7, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced its participation in upcoming October 2025 conferences and events.

Cell and Gene Meeting on the Mesa
What: Partnering and one-on-one meetings
When: October 6-8, 2025
Where: Arizona Biltmore, Phoenix, AZ
Who: Paul Romness, Chairman & CEO
How: OS Therapies is now a member of the Alliance for Regenerative Medicine

Roth Annual Healthcare Opportunities Conference
What: Meeting participation and one-on-one meetings
When: October 9, 2025
Where: Metropolitan Club, New York City, NY
Who: Gerald Commissiong, Chief Business Officer

FDA/The Osteosarcoma Institute (OSI) Workshop: Advancing Osteosarcoma Drug Development - Connecting Research and Regulatory Pathways for Improved Outcomes
What: Meeting participation and availability for sideline discussions
When: October 10, 2025
Where: Lincoln Square, Washington, DC
Who: OS Therapies Management & Regulatory Team

BIOFuture 2025
What: Spotlight Panel and one-on-one meetings
When: October 13-15, 2025
Where: Cure, New York City, NY
Who: Gerald Commissiong, Chief Business Officer

52nd Daytime Emmy Awards
Shelter Me: Cancer Pioneers - Nominated for 2 Emmy's trailer here movie here
What: Main awards presentation and select investor meetings
When: October 17, 2025
Where: Pasadena Civic Auditorium, Pasadena, CA
Who: Paul Romness, Chairman & CEO; Gerald Commissiong, Chief Business Officer; Nicola J. Mason, BVetMed, PhD, DACVIM, FRCVS, Veterinarian Advisor; and Serena Subada, Patient Advocate

Maxim Growth Summit: Maxim Group Healthcare Conference
What: Corporate presentation and one-on-one meetings
When: October 22, 2025
Where: Hard Rock Hotel, New York City, NY
Who: Paul Romness, Chairman & CEO; and Gerald Commissiong, Chief Business Officer

BIO - Europe
What: Partnering and one-on-one meetings
When: November 3-5, 2025
Where: Vienna, Austria
Who: Paul Romness, Chairman & CEO

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.